Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents

Journal of Antimicrobial Chemotherapy

Volumn 50, Issue 1, 2002, Pages 95-100

  Peric, Mihaela ^a   Lin, Gengrong ^a   Clark, Catherine L ^a   Jacobs, Michael R ^b   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADZ 2563; AMOXICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; POSIZOLID;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; CONTROLLED STUDY; DILUTION; DRUG ACTIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STREPTOCOCCUS; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STREPTOCOCCUS PNEUMONIAE;

EID: 0035996097     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkf080     Document Type: Article

References (24)

1. Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae
2. Antibiotic-resistant pneumococci
3. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study
4. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: Risk factors, susceptibility patterns and antimicrobial management
5. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae
6. Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States
7. Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: Characterization by penicillin-binding protein profile, surface protein A typing, and multi-locus enzyme analysis
8. Antimicrobial resistance in Streptococcus pneumoniae - An overview
9. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
10. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
11. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
12. Fluoroquinolone resistance in Streptococcus pneumoniae
13. In-vitro activity of linezolid against multiply resistant Gram-positive clinical isolates
14. Oxazolidinones. A review
15. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid
16. In-vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae
17. The in-vitro activity of linezolid (U-100766) and tentative break-points
18. Antipneumococcal activity of ABT-773 compared to those of 10 other agents
19. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae
20. Methods for Dilution Antimicrobial Susceptibility Tests for Bactefia that Grow Aerobically-Third Edition: Approved Standard M7-A4
21. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin and vancomycin by using time-kill methodology
22. Antipneurnococcal activities of RP 59500 (quinupristin/dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies
23. Quinupristin/dalfopristin and linezolid: Where, when, which and whether to use?
24. MIC and time-kill study of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci